Impact of distinct chemical structures for the development of a methamphetamine vaccine
about
Phage display--a powerful technique for immunotherapy: 2. Vaccine deliveryLipid tucaresol as an adjuvant for methamphetamine vaccine development.Simple radiometric method for accurately quantitating epitope densities of hapten-protein conjugates with sulfhydryl linkages.Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in miceSynthesis of mercapto-(+)-methamphetamine haptens and their use for obtaining improved epitope density on (+)-methamphetamine conjugate vaccines.A vaccine strategy that induces protective immunity against heroin.A conjugate vaccine attenuates morphine- and heroin-induced behavior in ratsAnti-addiction vaccines.Adjuvants for vaccines to drugs of abuse and addiction.Pharmacokinetic strategies for treatment of drug overdose and addiction.Effects of active anti-methamphetamine vaccination on intravenous self-administration in rats.Developing a vaccine against multiple psychoactive targets: a case study of heroin.Vaccines against drug abuse.Syntheses of Siderophore-Drug Conjugates Using a Convergent Thiol-Maleimide SystemEnhancing nicotine vaccine immunogenicity with liposomes.A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in ratsA vaccine against methamphetamine attenuates its behavioral effects in mice.Modulating cocaine vaccine potency through hapten fluorinationOptimization of a methamphetamine conjugate vaccine for antibody production in miceCombatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class DrugsChronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies.Probing the effects of hapten stability on cocaine vaccine immunogenicity.Nicotine vaccines to treat tobacco dependence.Conjugate Vaccine Immunotherapy for Substance Use Disorder.Biologics to treat substance use disorders: Current status and new directionsStructurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities.Methamphetamine Vaccines: Improvement through Hapten Design.Current status and future prospects for the development of substance abuse vaccines.Influencing Antibody-Mediated Attenuation of Methamphetamine CNS Distribution through Vaccine Linker Design.Current challenges for the creation of effective vaccines against drugs of abuse.A rapid solution-based method for determining the affinity of heroin hapten-induced antibodies to heroin, its metabolites, and other opioids.Rational design of a fluopyram hapten and preparation of bioconjugates and antibodies for immunoanalysis
P2860
Q26865013-4B812DA8-410D-4F00-9666-3E149EFA4D06Q33662748-336C67D8-F221-4F13-95DB-6964CA7D59B0Q34764446-DD751FC0-5004-49B7-8D1F-2BC7FD75DB7DQ35009554-08B0D61F-10B7-490B-B12C-BD35D0CF52E5Q35120379-D599DE73-5767-491A-AF15-BFCB1C37B547Q35126056-1A1EB19F-D677-45C1-A76A-AB9A668B8443Q35224297-1CE464B3-1290-428C-ABD5-80A0EC7715C1Q35263981-B944F863-B335-4B07-AFF2-BD80BE4020F9Q35493923-FC9FA427-254B-4401-89C0-209F7AA5FBA2Q35813574-07727AC6-4EB9-4620-91FC-5961E02308ADQ35875875-058A50DD-F61C-4DB0-8D1E-8DC61C9E3ADDQ35892296-12FC96E7-E959-4166-A6FA-2C27311E24CBQ35938624-24C9A23A-3950-4B8F-BA6A-DE7B21074DA8Q36474462-CBF661DD-2337-4694-9A93-6A14D33DED01Q36569318-14AD75F7-6483-42C8-80E4-D7A80600990BQ36579253-D0429628-DEB8-4FFB-B781-81BC4399AD0CQ36586100-B8F366E5-88A2-4B89-B504-B85E42F08395Q36798902-0F3851A7-51B8-4424-99FF-B4A1D2B408CCQ36854009-6BF692FB-0019-4B2E-94D8-F375781B4BE7Q36879970-0044E371-6F1D-40AC-B6AF-F6B828988DC0Q37264923-653A3E64-ED09-4C0A-89D7-1BEE51E89375Q37624530-5C76666F-4ABB-4353-9EC3-1FAFC82A360EQ38056382-377304E5-462B-4A21-B552-163D4026BABAQ39387013-8DD694CC-BF2F-40CA-BC76-95979B8D11C0Q39576940-69AA944E-CDD6-474E-BF90-3DAA90B80231Q40431126-65EC6BAF-08DB-412E-8E2F-97C6F8CBF9F4Q42113438-3BC78A7A-130C-41FC-A369-C3CBE83014C1Q43076031-6F43E37F-CDB6-4BA8-BAE9-35ED5971E4D1Q45257107-0A8ABE67-38B5-4616-B352-92AABD1E856BQ48214235-E61AEAB1-5CF2-4C12-BB81-32F28B4948E2Q52575567-C47D99BE-C459-425B-A5BD-B5BCCFB06B4DQ58478923-6D2595AE-F235-4210-8C87-9B0EF387F63A
P2860
Impact of distinct chemical structures for the development of a methamphetamine vaccine
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Impact of distinct chemical structures for the development of a methamphetamine vaccine
@ast
Impact of distinct chemical structures for the development of a methamphetamine vaccine
@en
Impact of distinct chemical structures for the development of a methamphetamine vaccine
@nl
type
label
Impact of distinct chemical structures for the development of a methamphetamine vaccine
@ast
Impact of distinct chemical structures for the development of a methamphetamine vaccine
@en
Impact of distinct chemical structures for the development of a methamphetamine vaccine
@nl
prefLabel
Impact of distinct chemical structures for the development of a methamphetamine vaccine
@ast
Impact of distinct chemical structures for the development of a methamphetamine vaccine
@en
Impact of distinct chemical structures for the development of a methamphetamine vaccine
@nl
P2093
P2860
P356
P1476
Impact of distinct chemical structures for the development of a methamphetamine vaccine
@en
P2093
Alexander V Mayorov
Amira Y Moreno
Kim D Janda
P2860
P304
P356
10.1021/JA108807J
P407
P577
2011-04-07T00:00:00Z